Top 20 of Neutropenia

Article title # Publications/# Citations

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

2000: ABonetti; CBoni; JCassidy; ACervantes; HCortés-Funes; FDe Braud; Ade Gramont; AFiger; ... GFreyer; DHendler; AHmissi; MHomerin; NLe Bail; CLouvet; FMorvan; DPapamichael; MSeymour; CWilson;

329

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

2000: SPAckland; CBlanke; JVCox; GLElfring; LFehrenbacher; PKLocker; JAMaroun; LLMiller; ... MJMoore; NPirotta; LSRosen; LBSaltz;

268

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

2006: MABlackwood-Chirchir; EBleickardt; TTChen; JCortes; APDecillis; NDonato; FHuang; VIyer; ... HKantarjian; CNicaise; JNicoll; SO'Brien; RPaquette; CLSawyers; NPShah; MTalpaz;

245

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.

1996: MFBrady; DLClarke-Pearson; MDavidson; WJHoskins; PRKucera; KYLook; WPMcGuire; EEPartridge;

209

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

1996: JMBennett; BDCheson; MGrever; NKay; MJKeating; SO'Brien; KRRai;

209

Nosocomial bloodstream infections in United States hospitals: a three-year analysis.

1999: MBEdmond; RNJones; DKMcClish; MAPfaller; SEWallace; RPWenzel;

203

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

2010: TROPIC Investigators; IBodrogi; JSDe Bono; GGravis; SGupta; SHansen; IKocak; JPMachiels; ... MJMackenzie; SOudard; MOzguroglu; MRoessner; AOSartor; LShen;

202

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

2008: NAmellal; MBenasso; CBokemeyer; DCupissol; Dde Raucourt; JErfan; RHitt; AKawecki; ... HRKienzer; RMesía; FPeyrade; ÉRemenár; FRivera; SRottey; ASchueler; JBVermorken; IVynnychenko; DZabolotnyy;

198

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

2004: PABunn; Fde Marinis; CDesch; LEinhorn; FVFossella; UGatzemeier; RGervais; NHanna; ... HLLim; CManegold; TMüller; PPaoletti; SPaul; JRPereira; MPless; Shaharyar; FAShepherd; KSzondy; TCTsao; Jvon Pawel;

181

The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

1987: MAFischl; MSGottlieb; MHGrieco; JEGroopman; MSHirsch; OLLaskin; JMLeedom; DMildvan; DDRichman; PAVolberding;

175

Comparison of caspofungin and amphotericin B for invasive candidiasis.

2002: Caspofungin Invasive Candidiasis Study Group; RBetts; ALColombo; NKartsonis; RLupinacci; JMora-Duarte; JPerfect; CRotstein; ... CSable; JSmietana; LThompson-Moya;

138

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

2005: AAnton; SChan; FCognetti; PConte; JMExtra; MGreen; DGrimes; JKennedy; ... ALluch; DMaraninchi; MMarty; LMauriac; KMayne; KO'Byrne; RSnyder; MTubiana-Hulin; CWard;

138

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

2010: ABC-02 Trial Investigators; AAnthoney; JBridgewater; DCunningham; SHughes; TIveson; SMadhusudan; AMaraveyas; ... DHPalmer; SPPereira; MRoughton; JValle; HWasan;

135

Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis.

2001: PMAllen; BTWipke;

135

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

2010: German Chronic Lymphocytic Leukaemia Study Group; International Group of Investigators; MBergmann; ABerrebi; SBöttcher; ABühler; RBusch; FCaligaris-Cappio; ... JCatalano; BCazin; HDöhner; BFEichhorst; GFingerle-Rowson; AMFink; KFischer; MHallek; MHensel; GHess; GHopfinger; UJäger; MKneba; JMayer; MMendila; MRitgen; JFSeymour; PStaib; SStilgenbauer; MTrneny; Uvon Grünhagen; CMWendtner; AWestermann; DWinkler; TZenz; PLZinzani;

130

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.

2007: DAngulo-Gonzalez; OACornely; YTGoh; CHardalo; DHelfgott; JHolowiecki; JMaertens; JPerfect; ... MPetrini; DStockelberg; RSuresh; AJUllmann; TJWalsh; DJWinston;

129

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

2006: JOArmitage; LBalducci; CLBennett; SBCantor; JCrawford; SJCross; GDemetri; CEDesch; ... JKhatcheressian; GHLyman; HOzer; PAPizzo; CASchiffer; LSchwartzberg; TJSmith; MRSomerfield; GSomlo; JCWade; JLWade; RJWinn; ACWolff; AJWozniak;

124

Aspergillosis case-fatality rate: systematic review of the literature.

2001: SJLin; JSchranz; SMTeutsch;

124

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.

2002: DArmstrong; GPBodey; EJBow; AEBrown; TCalandra; RFeld; WTHughes; PAPizzo; ... KVRolston; JLShenep; LSYoung;

122

Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization.

1994: SBasu; CCheers; ARDunn; KJFowler; DGrail; GHodgson; GJLieschke; DMetcalf; EStanley; YFZhan;

120